Agennix's Topical Talactoferrin Improved Healing of Diabetic Ulcers

Agennix has announced results from a randomized, placebo-controlled, NIH-sponsored, multicenter Phase II clinical trial evaluating topical talactoferrin alfa in diabetic neuropathic ulcers.

The trial met its primary endpoint -- incidence of greater than or equal to 75 percent healing at the end of dosing (Week 12) relative to baseline.

Patients receiving talactoferrin had double the incidence of 75 percent or greater healing compared to patients receiving placebo gel. There were no talactoferrin related adverse events or laboratory abnormalities.